Skip to main content
EJNMMI Research
Fig. 3 | EJNMMI Research

Fig. 3

From: 18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy

Fig. 3

Analysis of 18F-Fluciclovine PET SUV values [SUVmean (a), SUVpeak (b)] of CWR22Res (hormone-dependent) and 22Rv1 (castration-resistant) orthografts (two-way ANOVA, ***p < 0.0002, ns = not significant). c Coefficient of variation was calculated to assess the heterogeneity of 18F-Fluciclovine uptake within the CWR22Res and 22Rv1 orthografts. (n = 4 for CWR22Res and n = 3 for 22Rv1 orthografts)

Back to article page